Literature DB >> 25112232

Biomarkers: Sclerostin levels linked to CKD outcomes.

David Holmes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25112232     DOI： 10.1038/nrendo.2014.145

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  1 in total

1.  Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients.

Authors:  Mehmet Kanbay; Dimitrie Siriopol; Mutlu Saglam; Yasemin Gulcan Kurt; Mahmut Gok; Hakki Cetinkaya; Murat Karaman; Hilmi Umut Unal; Yusuf Oguz; Sebahattin Sari; Tayfun Eyileten; David Goldsmith; Abdulgaffar Vural; Gabriel Veisa; Adrian Covic; Mahmut Ilker Yilmaz
Journal:  J Clin Endocrinol Metab       Date:  2014-07-24       Impact factor: 5.958
  1 in total
  2 in total

1.  Ameliorative effect of chrysin on adenine-induced chronic kidney disease in rats.

Authors:  Badreldin H Ali; Sirin A Adham; Mohammed Al Za'abi; Mostafa I Waly; Javed Yasin; Abderrahim Nemmar; Nicole Schupp
Journal:  PLoS One       Date:  2015-04-24       Impact factor: 3.240

2.  How Accurate is Your Sclerostin Measurement? Comparison Between Three Commercially Available Sclerostin ELISA Kits.

Authors:  Isabelle Piec; Christopher Washbourne; Jonathan Tang; Emily Fisher; Julie Greeves; Sarah Jackson; William D Fraser
Journal:  Calcif Tissue Int       Date:  2016-01-09       Impact factor: 4.333
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.